ABOUT
Target Discovery is ushering in a new era of accurate and affordable bio/chemical testing, characterized by simplicity and certainty – regardless of the application.
We design cutting edge analytical solutions with “push-button” simplicity and instinctively clear reporting.
APPROACH
Our innovative testing strategies leverage the latest advances in analytical instrumentation, surface chemistry, microfluidics, nanotechnology, signal processing and machine learning.
We focus on users – making complexity disappear and providing affordable and accurate results, reported with clarity, speed and simplicity.
We embody the highest ethical standards, while delivering transformative value to our customers.
| Conventional Testing | TDI’s Testing | |
|---|---|---|
| Equipment | Expensive lab setup with complex technologies | Single, affordable, uniquely powerful desktop instrument |
| Scale | Requires large quantities of samples and chemicals | Performed on the microscale |
| Processes | Complex steps requiring highly trained/paid staff | Simple, failsafe steps |
| Multiplexing | Each test run separately | Tests integrated into a single run on a single platform |
| Analysis Time | Slow – hours to days per test | Rapid – minutes per test |
| Sustainability | Environmentally unfriendly processes | Safe, environmentally-friendly, green processes |
| Output | Difficult to interpret results | Accurate, easy-to-interpret, reports |
We enable our customers to offer the highest quality, safe and authentic products and services at low cost.
Discover the next generation in analytical testing with Target Discovery.
PROCESS
Begin with micro–scale handling of the sample.
Process through a simplified and automated workflow.
Access one-step push-button analysis.
Optimize results with powerful signal processing and machine learning.
Obtain an actionable, straightforward, statistically–driven report.
FOUNDATIONS
Target Discovery creates accurate, reproducible and robust processes that liberate our customers from dependence on expensive equipment, complex methods and the need for highly skilled, expert data interpretation.
Whether it is the complexities of posttranslational modifications of proteins in human tissues, or the challenges of detecting fraud or impurities in food products, Target Discovery is developing tools to robustly address customer needs across diverse markets.
At the heart of our approach, we optimize sample recovery and measurement, and apply high-performance computing strategies, advanced signal processing and machine learning to train, define, query and advise. We manage these complexities in the background and give you reliable, actionable, easy-to-interpret results.
IDENTITY
Mission
We are committed to improving the speed, cost, simplicity and accessibility of bio/chemical analysis, while at the same time, increasing the insights, meaningfulness and actionability of the information extracted from each analysis.
Vision
We see a world in which people are empowered and protected through access to relevant information about themselves, their nutrition and the environment in which they live.
LEADERSHIP
Jeffrey N. Peterson, Chief Executive Officer, co-founded Target Discovery, Inc. and its subsidiary, Veritomyx, Inc., where he leads as Chairman & CEO. Mr. Peterson also serves as Chairman of Pressure Biosciences, Inc. (PBIO) and of Imaging3 (IGNG). His broad executive leadership experience included a career in Abbott Laboratories, as CEO & GM of Abbott South Africa, and in pivotal roles in Abbott Diagnostics. He was previously CEO of SPO&A international business development consulting, and had a career rising through General Electric’s Engineered Materials and Plastics businesses. Mr. Peterson holds BSChemE and MSChemE degrees from MIT, and he has coauthored six issued patents and multiple scientific articles. Mr. Peterson serves on the Advisory Board for the California Technology Council, served 12 years on the Board of BayBio (CA Life Sciences Association) and is Chair Emeritus of the BayBio Institute. Mr. Peterson has been an active leader in the Coalition for 21st Century Medicine and in BIO’s Personalized Medicine & Diagnostics Group. He served on the University of Texas MD Anderson Cancer Center’s Board of Advisors for the Center for Professional Development and Entrepreneurship, and continues to advise rising entrepreneurs.
Mark W. Duncan, Ph.D., Chief Scientific Officer, has extensive experience in mass spectrometry, clinical diagnostics and analytical chemistry. Dr. Duncan holds B.Sc. (Hons) and Ph.D. degrees from the University of New South Wales. He was a Postgraduate Scholar at the Garvan Institute of Medical Research, Sydney, Australia and a Fogerty Fellow at the National Institute of Neurological Disorders & Stroke, National Institutes of Health (NIH), Bethesda, MD. He has held appointments as a Professor (Medicine) at Universities in Australia, the USA and Saudi Arabia and has established and directed MS resources at three international institutions. He has also held senior executive positions in industry and is a co-developer of Veristrat®, a blood-based diagnostic used in the management of patients with non-small cell lung cancer, marketed by Biodesix, Inc., Boulder, Colorado. He has published over 150 publications and has 8 issued patents. Dr. Duncan is co-editor, Special Features, Journal of Mass Spectrometry, he is on the editorial board, Journal of Clinical Mass Spectrometry and he is a member of the Committee on Quantitative Measurement of Proteins & Peptides by MS (C64), Clinical & Laboratory Standards Institute.
Thomas Schreck, Executive Director of Business Development, brings a wealth of expertise to Target Discovery. Before joining the team, he was Co-Founder, Vice Chairman and Chief Executive Officer of SinuSys Corp., a medical device company focused on developing new therapies to improve sinus health. Previously, Mr. Schreck was Co-Founder, Chairman and CEO of AcelRx, Inc. (ACRX), where he and his team co-invented, developed and enabled the commercialization of hand-held solutions for acute and post-operative pain control. Before co-founding AcelRx, he was Co-Founder, President and CFO of Durect Corporation (DRRX) where he was instrumental in the spin out of the DUROS drug delivery technology from Alza Corporation. He is a board member of Ekso Bionics (EKSO), an industry leader in stroke, spinal cord and traumatic brain injury rehabilitation. He also holds more than 30 U.S. patents. Mr. Schreck received a BA in American Civilization from Williams College.
Byron Miller, Intellectual Property Legal Consultant, has supported multiple pharmaceutical companies working in the immunology, cancer, age-related disease and neurodegenerative disease fields in recent years. Previously, Mr. Miller served as a part-time General Counsel of SinuSys Corp., a medical device company developing and marketing surgical tools for ENT applications. Prior to that, from 2002 to 2015, Mr. Miller served as Vice President and Chief Patent Counsel for XenoPort, Inc., a pharmaceutical company developing drugs for CNS diseases. Prior to 2002, he worked as an IP attorney for Alza Corp., a company focused on novel drug delivery systems, eventually becoming their chief patent counsel.